Karachi: BF Biosciences Limited has reported its financial results for the fiscal year ending June 30, 2026, showcasing a notable increase in revenue and profit margins. As disclosed in the company's annual report dated October 7, 2026, the pharmaceutical firm achieved a net revenue of 9.46 billion rupees, a significant increase from the prior year's 5.84 billion rupees.

The cost of goods sold for the year stood at 5.37 billion rupees, up from 3.55 billion rupees in 2025, leading to a gross profit of 4.09 billion rupees, compared to 2.29 billion rupees the previous year. Administrative expenses rose to 202.50 million rupees from 60.57 million rupees, while selling and distribution expenses increased to 2.70 billion rupees from 1.45 billion rupees.

The company's profit from operations was 1.17 billion rupees, up from 851.42 million rupees in the previous fiscal year. However, the finance cost decreased to 105.96 million rupees from 127.68 million rupees, contributing to a profit before minimum tax differential, final tax, and income tax of 1.07 billion rupees, compared to 723.74 million rupees a year earlier.

According to information available from the Pakistan Stock Exchange (PSX), BF Biosciences Limited's profit before income tax amounted to 1.06 billion rupees, up from 720.54 million rupees in 2025. The income tax expense for the year reached 424.64 million rupees, compared to 273.39 million rupees in the previous year.

Consequently, the profit after taxation for the year was recorded at 632.13 million rupees, reflecting a very large or significant move from 447.15 million rupees in the prior year. The earnings per share, both basic and diluted, increased to 7.16 rupees from 5.52 rupees.

The financial results underline BF Biosciences Limited's robust performance within the designated market category of pharmaceuticals, demonstrating substantial growth and profitability despite the increased expenses in administrative and selling operations.